Cardiac Complication Clinical Trial
Official title:
Incidence and Impact of Cardiac Dysfunction in Isolated Traumatic Brain Injury Patients Requiring Surgical Intervention
Verified date | June 2018 |
Source | National Institute of Mental Health and Neuro Sciences, India |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Patients with Head Injury have been associated with varying degree of cardiac dysfunction resulting in adverse events during emergency surgery and during recover from head injury. This study intends to study the incidence and impact of cardiac dysfunction using electrocardiogram, transthoracic echocardiogram and cardiac enzyme levels in head injury patients during and following emergency surgery. Our results will facilitate better management, guide specific therapy and help in prognostication in this group of patients.
Status | Completed |
Enrollment | 110 |
Est. completion date | January 15, 2018 |
Est. primary completion date | January 15, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients with isolated TBI requiring surgery - Surgery performed within 48 hours after insult Exclusion Criteria: - Presence of extracranial injuries (such as but not limited to orthopedic/ chest/ cardiac/ abdominal/ pelvis) - Penetrating craniocerebral injury - Pregnancy |
Country | Name | City | State |
---|---|---|---|
India | National Institute of Mental Health and Neurosciences | Bengaluru | Karnataka |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health and Neuro Sciences, India |
India,
Prathep S, Sharma D, Hallman M, Joffe A, Krishnamoorthy V, Mackensen GB, Vavilala MS. Preliminary report on cardiac dysfunction after isolated traumatic brain injury. Crit Care Med. 2014 Jan;42(1):142-7. doi: 10.1097/CCM.0b013e318298a890. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Left Ventricular Ejection Fraction < 50% and change following surgery | On ECHO performed using Ultrasonography (M-Turbo; Sonosite, Bothwell, WA, USA) using phased array transducer with a scanning frequency between 5 and 1 MHz - Ejection fraction calculated using simpson's Biplane method in 4 chamber and 2 chamber apical view. | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Primary | Incidence of Left ventricular regional wall motion abnormality and change following surgery | On ECHO performed using Ultrasonography (M-Turbo; Sonosite, Bothwell, WA, USA) using phased array transducer with a scanning frequency between 5 and 1 MHz - Presence of regional wall motion abnormality assessed in Parasternal - long and short axis, Apical 4,2 and 5 chamber views. | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormality - Tachycardia | ECG - heart rate > 100 min | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormality - Bradycardia | ECG - heart rate < 60/ min | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormaltiy - Prolonged PR interval | ECG - Prolonged PR Interval >200 ms | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormality - Prolonged QRS duration | ECG - Prolonged QRS duration >120 ms | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormality - ST-T changes | ECG - ST segment elevation and depression =0.1 mV in limb leads and =0.2 mV in chest leads, inverted (negative) T wave in any lead apart from aVR and V1 | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | ECG abnormality - Morphological End Repolarization abnormalities | ECG - T-wave showing biphasic, 2-peaked or separated U wave =0.1 mV | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | Elevated Cardiac Enzyme Levels | TROP I levels tested by i-STAT cTnI method on i-STAT device (Abbott Diagnostics, Abbott Park, IL) > 0.1 ng/mL. | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7. | |
Secondary | Short Term neurological outcome | Glasgow coma score (3-15) recorded at bedside. | Preoperative, Postoperative day 1, Postoperative day 2, Postoperative day 3, Postoperative day 4, Postoperative day 5, Postoperative day 6, Postoperative day 7, At 1 month. | |
Secondary | Hemodynamic Parameter - Cardiac Index | Cardiac Index values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Hemodynamic Parameter - Stroke volume index | Stroke volume index values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Hemodynamic parameter - Heart Rate | Heart rate values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Hemodynamic parameter - Mean Arterial Pressure | Mean Arterial Pressure values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Hemodynamic parameter - Stroke Volume Variation | Stroke Volume Variation values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Hemodynamic parameter - Systemic Vascular Resistance Index | Systemic Vascular Resistance Index values obtained from FloTrac transducer (FloTracTM, Edwards Lifesciences, Irvine, CA, USA) was used to connect the arterial line to the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA). | Continuous Values at 1 Min interval throughout the intraoperative period. | |
Secondary | Long term neurological outcome | Extended Glasgow Outcome score (1-8) | At 3 Months, At 6 months, At 1 year. | |
Secondary | Hospital Stay | Total number of days in hospital from admission to discharge | At 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
Completed |
NCT01423136 -
Remote Electrocardiographic (ECG) ST-Monitoring (PROSE 3)in Post-op Patients
|
N/A | |
Completed |
NCT05770336 -
STUDIO DELLE MANIFESTAZIONI CARDIOVASCOLARI A LUNGO TERMINE MEDIANTE TECNICHE DI IMAGING
|
||
Completed |
NCT04753762 -
Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection
|
||
Recruiting |
NCT03882580 -
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
|
||
Recruiting |
NCT05114408 -
Trimodal Prehabilitation in Patients Undergoing Elective Surgery
|
N/A | |
Completed |
NCT04501822 -
One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia
|
||
Terminated |
NCT04433546 -
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
|
Phase 2 | |
Completed |
NCT03413176 -
Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.
|
||
Completed |
NCT06268249 -
Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction
|
||
Recruiting |
NCT03209674 -
Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry
|
||
Recruiting |
NCT05762601 -
Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study
|
||
Not yet recruiting |
NCT05569798 -
The INSIGHT Feasibility Study Ultrasound in the Intensive Care Unit: A Randomised Controlled Feasibility Trial
|
N/A | |
Completed |
NCT03188341 -
Cardiac Complication After Vascular Surgery
|
N/A | |
Completed |
NCT03387540 -
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
|
||
Recruiting |
NCT05602298 -
The Quality of Recovery-15 Survey After Cardiac Surgery
|
||
Completed |
NCT04063397 -
Persistent Postpartum Cardiovascular Dysfunction in Patients With Preeclampsia
|
||
Completed |
NCT04013360 -
Acute Effect of Positive Expiratory Pressure Versus Breath Stacking Technique After Cardiac Surgery
|
N/A | |
Active, not recruiting |
NCT03892226 -
Cardiomyocyte Injury Following Acute Ischemic Stroke
|